

Ernest V. Linek examines the recent arguments and ruling in *Bristol-Myers Squibb v. Merck & Co.* in *Life Sciences Intellectual Property Review*

Ernest V. Linek discusses Merck's unsuccessful move to invalidate a Bristol-Myers Squibb patent covering metastatic skin cancer treatment in *Life Sciences Intellectual Property Review*.

In his article, Mr. Linek points out that the court's action may signal to the pharmaceutical industry that some methods of treatment claims, such as those in the BMS patent, can be the subject of Section 101 ineligibility analysis.

Please click [here](#) to read the article. Registration is required.

Posted: April 7, 2016